An Open-Label, Phase 1, First-In-Human Study of Safety and Tolerability of TRAIL Receptor Agonist ABBV-621 in Subjects With Previously Treated Solid Tumors and Hematologic Malignancies

What is the purpose of this trial?

This is an open-label, Phase I, dose-escalation study to determine the determine the maximum tolerated dose (MTD) and/or recommended phase two dose (RPTD), and evaluate the safety, efficacy, and pharmacokinetic (PK) profile of ABBV-621 for participants with previously treated solid tumors or hematologic malignancies. The study will consist of 2 segments: Segment I (Dose Escalation) and Segment II (Dose Expansion).

AbbVie Inc.

Start Date: 08/18/2017

End Date: 11/30/2018

Last Updated: 02/22/2018

Study HIC#: 2000020094